William K. Oh, MD, presented “mCRPC: Lu-177 PSMA and Beyond” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
How to cite: Oh, William K. “mCRPC: Lu-177 PSMA and Beyond.” October 17, 2024. Accessed Feb 2025. https://grandroundsinurology.com/mcrpc-lu-177-psma-and-beyond/
mCRPC: Lu-177 PSMA and Beyond – Summary
In this 24-minute presentation, William K. Oh, MD, a seasoned medical oncologist with over two decades of experience managing prostate cancer, discusses recent advancements in prostate cancer diagnosis and treatment, focusing on the transformative potential of PSMA diagnostics and LU-177 PSMA therapy.
Dr. Oh gives an overview of how PSMA diagnostics have revolutionized the identification of localized and metastatic prostate cancers, significantly altering clinical practice. He emphasizes the role of LU-177 in extending survival and improving the quality of life for patients with advanced prostate cancer, particularly those with metastatic castration-resistant prostate cancer (mCRPC).
Data from key clinical trials, including the VISION, TheraP, and SPLASH studies, are presented to highlight the efficacy of LU-177 in various stages of the disease. They demonstrate notable benefits in progression-free and overall survival rates compared to conventional therapies and underscore its potential in earlier treatment stages.
Dr. Oh reflects on the broader implications of PSMA-targeted treatments and theranostics for prostate cancer and potentially other cancers. This talk provides a comprehensive update on PSMA-based advancements and underscores the ongoing evolution of therapeutic strategies to enhance patient outcomes in prostate cancer care.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. William K. Oh is Chief Medical Officer at the Prostate Cancer Foundation (PCF), the world’s leading philanthropic organization dedicated to the eradication of prostate cancer and is also a Clinical Professor of Medicine in the Division of Hematology and Medical Oncology at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers.
Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. Dr. Oh completed a fellowship in medical oncology at the Dana-Farber Cancer Institute.
For two years prior to joining PCF, Dr. Oh was the Chief Medical Officer at Sema4, a patient-centered health intelligence company. From 2009-2020, Dr. Oh was Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute, an NCI-designated cancer center, at Mount Sinai. Dr. Oh spent 14 years at Harvard Medical School and the Dana-Farber Cancer Institute in Boston, including service as Clinical Director of GU Oncology and Associate Professor of Medicine.
Dr. Oh has authored more than 350 original articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), and the American Urological Association (AUA), including the Guidelines Committee for Castration-Resistant Prostate Cancer. In addition to reviewing for prominent journals such as the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh was inducted into the prestigious American Society for Clinical Investigation (ASCI) and has been repeatedly selected as a Top Doctor in New York Magazine, Castle Connolly, Best Doctors, and Super Doctors.
